X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (21) 21
hematology (18) 18
humans (18) 18
hemic and lymphatic diseases (13) 13
article (11) 11
aged (9) 9
expression (8) 8
ibrutinib (8) 8
male (8) 8
abridged index medicus (7) 7
b-cells (7) 7
female (7) 7
immune system diseases (7) 7
leukemia (7) 7
leukemia, lymphocytic, chronic, b-cell - drug therapy (7) 7
leukemia, lymphocytic, chronic, b-cell - pathology (7) 7
lymphoma (7) 7
middle aged (7) 7
survival (7) 7
animals (6) 6
apoptosis (6) 6
cll (6) 6
mice (6) 6
microenvironment (6) 6
oncology (6) 6
chemokines (5) 5
chronic lymphatic leukemia (5) 5
lymphoid neoplasia (5) 5
migration (5) 5
pyrazoles - therapeutic use (5) 5
pyrimidines - therapeutic use (5) 5
t-cells (5) 5
therapy (5) 5
activation (4) 4
adult (4) 4
aged, 80 and over (4) 4
antineoplastic agents - therapeutic use (4) 4
b cell receptor (4) 4
cancer (4) 4
cell survival - drug effects (4) 4
cells, cultured (4) 4
chronic lymphocytic leukemia (4) 4
chronic lymphocytic-leukemia (4) 4
immunology (4) 4
initial therapy (4) 4
lymphatic leukemia (4) 4
protein-tyrosine kinases - antagonists & inhibitors (4) 4
rituximab (4) 4
signal transduction - drug effects (4) 4
tumor cells, cultured (4) 4
analysis (3) 3
antineoplastic agents - pharmacology (3) 3
apoptosis - drug effects (3) 3
b cells (3) 3
b-cell receptor (3) 3
blotting, western (3) 3
btk (3) 3
cd38 expression (3) 3
cell line, tumor (3) 3
cell movement - drug effects (3) 3
cell proliferation - drug effects (3) 3
chemokine ccl3 - secretion (3) 3
chemokine ccl4 - secretion (3) 3
cyclophosphamide (3) 3
drug resistance (3) 3
enzyme-linked immunosorbent assay (3) 3
flow cytometry (3) 3
fludarabine (3) 3
leukemia, hairy cell - pathology (3) 3
mutation (3) 3
prognosis (3) 3
pyrazoles - administration & dosage (3) 3
pyrimidines - administration & dosage (3) 3
pyrimidines - pharmacology (3) 3
receptor (3) 3
signal transduction (3) 3
stromal cells - drug effects (3) 3
surface igm (3) 3
tyrosine (3) 3
antigen receptors (2) 2
antineoplastic agents - administration & dosage (2) 2
b-lymphocytes - drug effects (2) 2
b-lymphocytes - immunology (2) 2
bcr (2) 2
blood (2) 2
bone marrow cells - drug effects (2) 2
bone marrow cells - metabolism (2) 2
cell adhesion - drug effects (2) 2
cell migration (2) 2
cell proliferation (2) 2
cell survival (2) 2
chemokine ccl3 - metabolism (2) 2
chemokine ccl4 - metabolism (2) 2
chemokine receptors (2) 2
chlorambucil (2) 2
coculture techniques (2) 2
cxcr4 (2) 2
development and progression (2) 2
disease progression (2) 2
dna-binding proteins - metabolism (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Communications, ISSN 2041-1723, 05/2016, Volume 7, Issue 1, p. 11589
  Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using... 
Journal Article
Best Practice & Research: Clinical Haematology, ISSN 1521-6926, 2015, Volume 28, Issue 4, pp. 208 - 216
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 9, pp. 2154 - 2158
Background: Ibrutinib is an active therapy with an acceptable safety profile for patients with chronic lymphocytic leukemia (CLL), including high-risk patients... 
TRIAL | CLL | ONCOLOGY | INITIAL THERAPY | Therapy | Chronic lymphatic leukemia | Cell survival | Risk groups | Leukemia | p53 Protein | Medical treatment | Stem cell transplantation | Rituximab | Risk | Transplantation | Lymphatic leukemia | Survival | Patients | Clonal deletion | Experimental design | Safety engineering | Deletion | Remission | Fatalities | Mutation | Cancer | deletion 17p | chronic lymphocytic leukemia | Ibrutinib | rituximab
Journal Article
Journal of Immunology, ISSN 0022-1767, 02/2017, Volume 198, Issue 4, pp. 1740 - 1747
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, p. e83830
CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3K... 
B-CELLS | SURVIVAL | MIGRATION | APOPTOSIS | CAL-101 | MICROENVIRONMENT | MULTIDISCIPLINARY SCIENCES | MOLECULE-1 | TYROSINE KINASE INHIBITOR | RECEPTOR | EXPRESSION | Cell Survival - drug effects | Integrin alpha4beta1 - metabolism | Purines - pharmacology | Stromal Cells - pathology | Bone Marrow Cells - pathology | Enzyme Inhibitors - pharmacology | Cell Adhesion - drug effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Integrins - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Animals | Signal Transduction - drug effects | Stromal Cells - drug effects | Cell Line, Tumor | Mice | Gene Expression Regulation, Neoplastic - drug effects | Endothelial Cells - pathology | Vascular Cell Adhesion Molecule-1 - metabolism | Quinazolinones - pharmacology | Endothelial Cells - drug effects | B cells | Analysis | Integrins | Endothelium | Cell culture | Vascular cell adhesion molecule 1 | Phosphorylation | Pathogenesis | Leukemia | Shear flow | Trafficking | AKT protein | Kinases | Tissues | VLA-4 antigen | Blood | Lymph nodes | Cell adhesion & migration | Atrophy | Cell growth | Immunology | Lymphocytes | Compartments | Cell adhesion | Bone marrow | Inhibition | Antigens | Chronic lymphatic leukemia | CD49d antigen | Hematology | Internal medicine | Shrinkage | Lymphatic leukemia | Tumor necrosis factor-α | Adhesion | 1-Phosphatidylinositol 3-kinase | Inhibitors | Stromal cells | Lymphomas | Lymphocytosis | Binding sites | Chemokines | Apoptosis | Cancer
Journal Article
Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 2185 - 12
Treatment of chronic lymphocytic leukemia (CLL) has shifted from chemo-immunotherapy to targeted agents. To define the evolutionary dynamics induced by... 
B-CELL LYMPHOMA | TUMOR-MICROENVIRONMENT | MULTIDISCIPLINARY SCIENCES | INITIAL THERAPY | RESISTANCE | CLONAL EVOLUTION | MUTATIONS | SEQUENCING DATA | SINGLE-ARM | GENOME | PROGRESSION | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Clonal Evolution - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Rituximab - therapeutic use | Phospholipase C gamma - genetics | Aged, 80 and over | Adult | Female | Gene Expression Regulation, Neoplastic - drug effects | Molecular Targeted Therapy - methods | Pyrazoles - pharmacology | Signal Transduction | Clonal Evolution - drug effects | Down-Regulation | Treatment Outcome | Pyrimidines - pharmacology | Disease Progression | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Whole Exome Sequencing | Rituximab - pharmacology | Drug Resistance, Neoplasm - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Mutation | Longitudinal Studies | Drug Resistance, Neoplasm - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Lymphocyte receptors | Therapy | Energy metabolism | Chronic lymphatic leukemia | Transcription | Leukemia | Lymphatic leukemia | Metabolism | Drug resistance | Gene expression | Bruton's tyrosine kinase | Signaling | Lymphocytes B | Immunotherapy | Cell cycle | Evolution | Cancer
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2014, Volume 166, Issue 2, pp. 177 - 188
B cell receptor ( BCR ) signalling plays a critical role in the progression of several B ‐cell malignancies, but its role in hairy cell leukaemia ( HCL ) is... 
microenvironment | ibrutinib | hairy cell leukaemia | bruton tyrosine kinase | cell receptor | Bruton tyrosine kinase | Microenvironment | B cell receptor | Ibrutinib | Hairy cell leukaemia | MIGRATION | DIAGNOSIS | TUMOR-CELLS | CLADRIBINE | ANTIGEN RECEPTORS | CHRONIC LYMPHOCYTIC-LEUKEMIA | MALIGNANCIES | LYMPHOMA | HEMATOLOGY | EXPRESSION | Chemokine CXCL12 - physiology | Protein-Tyrosine Kinases - metabolism | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Receptors, Antigen, B-Cell - metabolism | Neoplasm Proteins - metabolism | Chemokine CXCL12 - antagonists & inhibitors | Dose-Response Relationship, Drug | Adult | Chemokine CCL3 - metabolism | Chemokine CCL4 - metabolism | Female | Receptors, Antigen, B-Cell - physiology | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Tumor Cells, Cultured | Leukemia, Hairy Cell - pathology | Pyrazoles - pharmacology | Cell Survival - drug effects | Drug Evaluation, Preclinical - methods | Pyrimidines - administration & dosage | Leukemia, Hairy Cell - genetics | Pyrimidines - pharmacology | Pyrazoles - administration & dosage | Leukemia, Hairy Cell - metabolism | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Aged | Cell Proliferation - drug effects | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Phenols | Health aspects | Phosphotransferases
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 114, Issue 5, pp. 1029 - 1037
Antigenic stimulation through the B-cell antigen receptor (BCR) is considered to promote the expansion of chronic lymphocytic leukemia (CLL) B cells. The... 
SURFACE IGM | APOPTOSIS | CLL | NURSELIKE CELLS | SYK | CHEMOKINE RECEPTOR | LYMPHOMA | GENE MUTATIONAL STATUS | CD38 EXPRESSION | HEMATOLOGY | MARROW STROMAL CELLS | Chemokine CCL3 - secretion | Chemokine CCL4 - secretion | Cell Adhesion Molecules - genetics | Coculture Techniques | Humans | Middle Aged | Neoplasm Proteins - physiology | Male | Neoplasm Proteins - antagonists & inhibitors | Protein-Tyrosine Kinases - physiology | Chemotaxis - physiology | Neoplasm Proteins - secretion | Protein Processing, Post-Translational - drug effects | Receptors, Chemokine - biosynthesis | Aged, 80 and over | Adult | Female | Receptors, Antigen, B-Cell - physiology | Antineoplastic Agents - pharmacology | Receptors, Chemokine - genetics | Syk Kinase | Cell Survival - physiology | Oxazines - pharmacology | Cell Survival - drug effects | Cell Adhesion Molecules - biosynthesis | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Chemotaxis - drug effects | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Animals | Signal Transduction - drug effects | Lymphocyte Activation - drug effects | Aged | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Intracellular Signaling Peptides and Proteins - physiology | Stromal Cells - physiology | Drug Screening Assays, Antitumor | Protein-Tyrosine Kinases - antagonists & inhibitors | Lymphoid Neoplasia
Journal Article
Journal Article
Leukemia & lymphoma, ISSN 1042-8194, 07/2019, pp. 1 - 9
CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity.... 
Journal Article
Journal Article